Patents by Inventor Ralph Adams

Ralph Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10562966
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: February 18, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters, Ralph Adams, James Heads
  • Publication number: 20200048372
    Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab? fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.
    Type: Application
    Filed: July 11, 2019
    Publication date: February 13, 2020
    Inventors: Ralph Adams, Laura Hancock, Sam Philip Heywood
  • Patent number: 10478945
    Abstract: An abrasive recovery system for a waterjet cutter, the abrasive recovery system comprising: a drain coupler including at least one drain nozzle, the drain nozzle having at least one wall defining a drain nozzle bore, the drain coupler defining a drain opening wherein the drain opening is in fluid communication with the drain nozzle bore; and a flexible hose coupled to the drain nozzle to establish fluid communication between the drain opening and the flexible hose.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 19, 2019
    Assignee: HMCC ACQUIRECO2, LLC
    Inventors: Richard Ralph Ward, Benjamin J. Adams
  • Publication number: 20190343972
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Application
    Filed: July 24, 2019
    Publication date: November 14, 2019
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria N. Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, JR., Ralph Adam Smith, Virginie Lafont, Daniel Cohen
  • Patent number: 10430883
    Abstract: Methods, computer-readable media, systems and apparatuses for determining and implementing dynamic usage-based insurance policies are presented. A cost per day and a cost per mile associated with the dynamic usage-based insurance policy may be determined. The cost per mile may be computed independently for each of a plurality of road segments comprising a trip based on a time of day that the vehicle traveled each road segment, a road type associated with each road segment. The cost per mile of each road segment of the driving trip may further include whether or not hard braking or hard cornering events were encountered during a specified cumulative driving distance that may include, at least a portion, of a plurality of driving trips. The cost per mile for each of the plurality of driving trips may be adjusted once a threshold distance has been traveled by the vehicle based on the number of hard braking events and hard cornering events occurred during that distance.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: October 1, 2019
    Assignee: Allstate Insurance Company
    Inventors: Christine L. Bischoff, Dana Ferguson, Eric D. Huls, Grady Irey, William Polisson, Caryl M. Styrsky, Ralph Adam Benjamin Tyner, Meg G. Walters
  • Patent number: 10421816
    Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 24, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Emma Dave, David Paul Humphreys
  • Publication number: 20190282744
    Abstract: A blood pump assembly can include various components such as a housing and a sensor configured to detect one or more characteristics of the blood. In some embodiments, the sensor can be coupled to the housing and can include a sensor membrane configured to deflect in response to a change in a blood parameter (e.g., pressure). The blood pump assembly can include a shield that covers at least a portion of the sensor membrane so as to protect the sensor from damage when the blood pump assembly is inserted through an introducer and navigated through the patient's vasculature and/or when the blood pump assembly is inserted into the heart in a surgical procedure. One or more protective layers can be deposited over the sensor membrane to prevent the sensor membrane from being dissolved through interactions with the patient's blood.
    Type: Application
    Filed: June 6, 2019
    Publication date: September 19, 2019
    Inventors: Ralph Louis D'Ambrosio, Bruce Adams, Michael Thomas Finnegan, Gerd Spanier, Thorsten Siess
  • Patent number: 10407513
    Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab? fragment and one or more single domain antibodies which may be stabilized by a disulfide bond therebetween.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: September 10, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Laura Hancock, Sam Philip Heywood
  • Patent number: 10406251
    Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 10, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria N. Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen
  • Publication number: 20190233530
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • Patent number: 10342906
    Abstract: A blood pump assembly can include various components such as a housing and a sensor configured to detect one or more characteristics of the blood. In some embodiments, the sensor can be coupled to the housing and can include a sensor membrane configured to deflect in response to a change in a blood parameter (e.g., pressure). The blood pump assembly can include a shield that covers at least a portion of the sensor membrane so as to protect the sensor from damage when the blood pump assembly is inserted through an introducer and navigated through the patient's vasculature and/or when the blood pump assembly is inserted into the heart in a surgical procedure. One or more protective layers can be deposited over the sensor membrane to prevent the sensor membrane from being dissolved through interactions with the patient's blood.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: July 9, 2019
    Assignee: ABIOMED, INC.
    Inventors: Ralph Louis D'Ambrosio, Bruce Adams, Michael Thomas Finnegan, Gerd Spanier, Thorsten Siess
  • Publication number: 20190184042
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Application
    Filed: May 31, 2017
    Publication date: June 20, 2019
    Inventors: Paul E. MORIN, David DONNELLY, Dasa LIPOVSEK, Jochem GOKEMEIJER, Maria JURE-KUNKEL, David FABRIZIO, Martin C. WRIGHT, Douglas DISCHINO, Samuel J. BONACORSI, Jr., Ralph Adam SMITH, Virginie LAFONT, Daniel COHEN, David K. LEUNG
  • Patent number: 10308723
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: June 4, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Publication number: 20190161536
    Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
    Type: Application
    Filed: November 20, 2018
    Publication date: May 30, 2019
    Applicants: President and Fellows of Harvard College, UCB Biopharma SPRL
    Inventors: Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson
  • Publication number: 20190144565
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
  • Publication number: 20190144529
    Abstract: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 16, 2019
    Inventors: Ralph ADAMS, Sam Philip HEYWOOD
  • Patent number: 10160798
    Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 25, 2018
    Assignees: President and Fellows of Harvard College, UCB Biopharma SPRL
    Inventors: Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson
  • Publication number: 20180346561
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: May 8, 2018
    Publication date: December 6, 2018
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Patent number: 10023631
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: July 17, 2018
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Pallavi Bhatta, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 9988446
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: June 5, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson